SURF is a randomised controlled, parallel group, single blind phase II study designed to assess the safety and potential efficacy of an innovative therapeutic strategy for urethral stenosis based on adjuvant injection of autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF) during endoscopic urethrotomy (standard care).
Age range
18 Years – 85 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Baseline intensity and duration of urethral pain
Timeframe: 1 day
Intensity and duration of urethral pain D7
Timeframe: 7 days
Intensity and duration of urethral pain M1
Timeframe: 1 month
Intensity and duration of urethral pain M3
Timeframe: 3 months
Intensity and duration of urethral pain M6
Timeframe: 24 months
Intensity and duration of urethral pain M9
Timeframe: 9 months
Intensity and duration of urethral pain M18
Timeframe: 18 months
Intensity and duration of urethral pain M24
Timeframe: 24 months
Incidence of urinary infection
Timeframe: 24 months
Incidence of urniary infection M1
Timeframe: 1 month
Number of patient with urethral bleeding
Timeframe: 1 day
Number of patient with urethral bleeding D7
Timeframe: 7 days
Number of patient with urethral bleeding M1
Timeframe: 1 month
Number of patient with urethral bleeding M3
Timeframe: 3 months
Number of patient with urethral bleeding M6
Timeframe: 6 months
Number of patient with urethral bleeding M9
Timeframe: 9 months
Number of patient with urethral bleeding M18
Timeframe: 18 months
Number of patient with urethral bleeding M24
Timeframe: 24 months
Presence of urethral perforation with fistula or perineal soft tissue infection D7
Timeframe: 7 days
Presence of urethral perforation with fistula or perineal soft tissue infection M1
Timeframe: 1 month
Presence of urethral perforation with fistula or perineal soft tissue infection M3
Timeframe: 3 months
Presence of urethral perforation with fistula or perineal soft tissue infection M6
Timeframe: 6 months
Presence of urethral perforation with fistula or perineal soft tissue infection M9
Timeframe: 9 months
Presence of urethral perforation with fistula or perineal soft tissue infection M18
Timeframe: 18 months
Presence of urethral perforation with fistula or perineal soft tissue infection M24
Timeframe: 24 months